Euronext Tech 40 issuers outperform
Euronext has announced the new composition of its Tech 40 label, which recognises 40 innovative European small and mid-cap companies listed on its markets.
This year, 12 new companies are entering in the new label composition, selected by a group of independent European experts, based on capital markets, economic and financial performance criteria. The companies are also added to the index, composed exclusively of the labelled Tech 40 stocks.
Euronext launched the Tech 40 label two years ago to increase the exposure of promising tech companies that are listed on its markets. The index for these shares rose by +25 per cent year on year. The 40 labelled companies have a combined revenue of EUR10 billion, 45,000 employees and total market capitalisation of EUR14.5 billion.
The Tech 40 initiative is among one of the several programmes developed by EnterNext, the Euronext subsidiary dedicated to the promotion of listed small and mid-cap tech companies. EnterNext assists tech companies in their listings and help raise their profile on the financial markets.
Its initiatives include: the TechShare programme which aims to help unlisted tech companies’ executives to better understand the role and operations of the financial markets; a partnership with Morningstar to strengthen investors’ knowledge and financial analysis of tech stocks; and the launch of The Tech Corner, a web platform dedicated to the market financing of the tech sector.
The members of the new Tech 40 label (new members in bold) are:
1000Mercis , Ablynx, Actia Group, AGFA-Gevaert, Albioma, Ateme, Aufeminn, Axway Software, Barcio, Blue Solutions, Cellectis, Celyad, CTAC, Environment SA, Erytech Pharma, Genfit, Global Bioenergies, Groupe Gorge; Groupe LDLC, Impresa SGPSMPRESA,SGPS; Innate Pharma, MDXHealth, Media Capital, MedianTechnologies, Mersen, MGI Digital Graphi, NanoBiotix, Neways Electronics, Novabase SGPS, Onxeo, Ordina, Reworld Media, SES Imagotag, ShowroomPrive, SoiTec, Valneva, Voltalia, Wavestone, Ymagis, and Zenitel.